| Products/Services Used | Details | Operation |
|---|---|---|
| Proteins, Expression, Isolation and Analysis | All the constructed expression plasmids were transfected into COS-7 cells with lipofectamine 2000 (Life Technologies, Carlsbad, CA, USA) to produce human and mouse immunoglobulin (IgG)-Fc or his-tag fusion proteins, which were subsequently puri?ed using rProtein A Sepharose (GE Healthcare, Uppsala, Sweden) or Ni-NTA Agarose Resin (GenScript Co. | Get A Quote |
Immune checkpoint inhibitors result in impressive clinical responses and are expanding to treat a wide variety of tumors. One common problem is low responses from current clinical trials that only benefit a fraction of patients. One key promising direction is combination therapy to increase clinical benefit. CD137, a well-defined antitumor target, can cause strong co-stimulating activity and break immune tolerance. In this study, the role of CD137-CRDI (cysteine rich domain I) in the binding of CD137-CD137L was further investigated based on our previous work. The results revealed that CRDI-mediated limited CD137 assembly without relying on CD137L. Furthermore, CRDI was not involved in direct contact with CD137L... More
